Cypress Bioscience Genomic Tests Firm Exagen Buying Cypress’ Dx Biz Exagen will pay Cypress up to $8 million in upfront and milestone payments as well as additional royalty payments for the business. Marina to Sell off Non-RNAi Asset to Cypress Bioscience Premium Under the deal, Marina will receive $750,000 up front, and stands to be paid as much as $27 million in milestones. Cypress Bioscience Test Gets Positive Medicare Reimbursement Decision The firm offers its Avise PG test as a service for physicians making decisions about methotrexate therapy. Cypress Acquires Personalized Medicine Technology from Cellatope Cypress will pay up to $5 million for the technology, which it plans to use for diagnosis and therapeutic monitoring of lupus patients. Breaking News Gastric Cancer Chemotherapy Response, Prognoses Predicted With Blood-Based Immune Proteomics International Commission to Expand Molecular Testing Access for Cancer Patients NYU Langone Perlmutter Cancer Center to Validate Biological Dynamics Pancreatic Cancer Test SomaLogic Expands Into Middle East With Proteomics Supply Deal for Group 42 Healthcare Arima Genomics to Offer NGS-Based Gene Fusion Test Through Protean BioDiagnostics CLIA Lab The Scan Drug Response Variants May Be Distinct in Somatic, Germline Samples Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline. Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine. Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures. Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.